logo
Plus   Neg
Share
Email

Jazz Pharma To Sell Women's Health Unit To Meda - Quick Facts

Jazz Pharmaceuticals plc (JAZZ) entered into a definitive agreement to sell its women's health business, comprising six products, to Meda, an international specialty pharmaceutical company, for $95 million cash. The sale includes products like Elestrin, Gastrocrom, Natelle One, AVC Cream, Gesticare DHA and Urelle. Net sales for these products in 2011 totaled $30.4 million.

According to the transaction, Meda would offer positions to nearly 60 Jazz Pharmaceuticals employees who directly support these products. Jazz Pharmaceuticals expects to recognize a non-recurring gain on the sale in the fourth quarter of 2012. The company intends to provide more detail about the financial impact of the transaction after closing. The transaction may close in the fourth quarter of 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT